Rescue Hearing
Rescue Hearing Inc. is a biotechnology company developing gene therapies and related diagnostic approaches to treat genetic causes of hearing and balance disorders. The organization advances preclinical and clinical-stage programs that target specific inner-ear genes, integrates molecular imaging and genetic diagnostics for patient selection, conducts natural-history studies to inform trial design, and pursues strategic licensing and partnership opportunities to advance programs toward clinical development.
Industries
Nr. of Employees
small (1-50)
Rescue Hearing
Patents
Products
DFNB8 gene therapy program
Development program addressing a genetic form of progressive post-lingual hearing loss; program activities include preclinical development and strategic licensing.
DFNB16 (STRC) gene therapy program
Program targeting STRC-associated congenital or progressive hearing loss (DFNB16), focusing on restoring inner-ear hair-cell function.
USH1B (MYO7A) gene therapy program
Program developed to address MYO7A-associated Usher syndrome with attention to both hearing and vestibular (balance) dysfunction.
DFNB77 gene therapy candidate
Preclinical candidate program addressing a nonsyndromic form of genetic hearing loss observed in cochlear-implant populations.
Otarmeni
An AAV-based gene therapy approved for pediatric and adult patients with severe-to-profound or profound sensorineural hearing loss associated with molecularly confirmed variants in both copies of the OTOF gene.
MYO7A
Gene therapy program targeting genetic mutations associated with Usher's disease and hearing/balance disorders, acquired by MED-EL.
DFNB8 gene therapy program
Development program addressing a genetic form of progressive post-lingual hearing loss; program activities include preclinical development and strategic licensing.
DFNB16 (STRC) gene therapy program
Program targeting STRC-associated congenital or progressive hearing loss (DFNB16), focusing on restoring inner-ear hair-cell function.
USH1B (MYO7A) gene therapy program
Program developed to address MYO7A-associated Usher syndrome with attention to both hearing and vestibular (balance) dysfunction.
DFNB77 gene therapy candidate
Preclinical candidate program addressing a nonsyndromic form of genetic hearing loss observed in cochlear-implant populations.
Otarmeni
An AAV-based gene therapy approved for pediatric and adult patients with severe-to-profound or profound sensorineural hearing loss associated with molecularly confirmed variants in both copies of the OTOF gene.
MYO7A
Gene therapy program targeting genetic mutations associated with Usher's disease and hearing/balance disorders, acquired by MED-EL.
Services
Design and conduct of longitudinal natural-history studies and maintenance of mutation-specific patient datasets to inform trial endpoints and regulatory strategy.
Preclinical program development including AAV vector optimization, in vivo efficacy testing, and translational assay development for inner-ear gene therapies.
Design and conduct of longitudinal natural-history studies and maintenance of mutation-specific patient datasets to inform trial endpoints and regulatory strategy.
Preclinical program development including AAV vector optimization, in vivo efficacy testing, and translational assay development for inner-ear gene therapies.
Expertise Areas
- Gene therapy development for auditory and vestibular disorders
- Inner-ear delivery and translational otology
- Natural history study design and patient registry development
- Preclinical models and vector development
Key Technologies
- Adeno-associated virus (AAV) vector platforms
- CRISPR/Cas9 gene editing
- Local cochlear (inner-ear) delivery techniques
- Molecular imaging
News & Updates
Press release announcing acquisition of two gene therapy programs addressing MYO7A and STRC programs; transaction transfers full rights for further development and commercialization.
Press release describing a novel gene therapy technique designed to restore hearing in individuals affected by STRC-related hearing loss.
Announcement of presentation of preclinical proof-of-concept data using AAV-mediated approaches in inner-ear research.
Press release announcing a strategic research partnership to advance a gene therapy program.
Announcement of appointment of a physician-scientist with expertise in inner-ear regeneration, optogenetics, and translational therapies to the scientific advisory board.
Presentation of AAV-mediated inner-ear proof-of-concept data at a major otolaryngology research meeting.
Press release announcing acquisition of two gene therapy programs addressing MYO7A and STRC programs; transaction transfers full rights for further development and commercialization.
Press release describing a novel gene therapy technique designed to restore hearing in individuals affected by STRC-related hearing loss.
Announcement of presentation of preclinical proof-of-concept data using AAV-mediated approaches in inner-ear research.
Press release announcing a strategic research partnership to advance a gene therapy program.
Announcement of appointment of a physician-scientist with expertise in inner-ear regeneration, optogenetics, and translational therapies to the scientific advisory board.
Presentation of AAV-mediated inner-ear proof-of-concept data at a major otolaryngology research meeting.